Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of PF-08653944 in Adults With and Without Hepatic Impairment
NCT07519135Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-08653944 (4 arms), sponsored by Pfizer. Primary endpoints: Maximum observed plasma concentration at 11 weeks and Area under the plasma concentration-time curve at 11 weeks. Started Apr 2026; status: recruiting.
02
Drugs
PF-08653944
Beyond the preview
Go deeper on NCT07519135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519135.